Midlife PSA Levels Can Predict Future Lethal Prostate Cancer

This article originally appeared here.
Share this content:
Midlife PSA Levels Predict Future Lethal Prostate Cancer
Midlife PSA Levels Predict Future Lethal Prostate Cancer

(HealthDay News) -- Prostate-specific antigen (PSA) levels in midlife predict future lethal prostate cancer (PCa) risk, according to a study published online June 13 in the Journal of Clinical Oncology.

Mark A. Preston, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues conducted a nested case-control study among men aged 40 to 59 years who gave blood before being randomized in the Physicians' Health Study trial of aspirin and β-carotene. Baseline PSA levels were available for 234 patients with PCa and 711 controls matched for age; the authors then rematched 71 patients with lethal PCa to 213 controls.

The researchers found that for men aged 40 to 49, 50 to 54, and 55 to 59 years, the median PSA among controls was 0.68, 0.88, and 0.96 ng/mL. There was a strong correlation between the risk of lethal PCa and baseline PSA in midlife: comparing PSA in the >90th percentile versus less than or equal to median correlated with odds ratios of 8.7, 12.6, and 6.9 at 40 to 49 years, 50 to 54 years, and 55 to 59 years, respectively. For men aged 40 to 49, 50 to 54, and 55 to 59 years, a total of 82, 71, and 86 percent, respectively, of lethal cases occurred among those with PSA above the median.

"Risk-stratified screening on the basis of midlife PSA should be considered in men age 45 to 59 years," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs